Humulin I (Isofano) (Insulin Human (Rdna))

Humulin I (Isofano) is indicated for the management of hyperglycemia in patients with diabetes mellitus.

• Type 1 diabetes mellitus, as basal insulin to replace deficient endogenous insulin.
• Type 2 diabetes mellitus, when diet, exercise, and oral agents do not achieve glycemic targets.
• Adjunct to oral antidiabetic drugs in patients requiring additional insulin support.
• Use during pregnancy or lactation only when the potential benefit outweighs risk, under medical supervision.
• Off‑label use in certain cases of gestational diabetes as directed by a specialist.
• Combination therapy with rapid‑acting insulin analogues for flexible dosing schedules.

• Humulin I (Isofano) contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers the intracellular tyrosine‑kinase cascade, leading to translocation of GLUT‑4 transporters and increased glucose uptake in peripheral tissues. In the liver, the signal suppresses gluconeogenesis and glycogenolysis while promoting glycogen synthesis, thereby lowering circulating blood glucose levels and improves overall metabolic control.

Adverse reactions to Humulin I (Isofano) are generally related to its pharmacologic activity and formulation.

Common

• Mild hypoglycemia, presenting as shakiness, sweating, or hunger.
• Injection site reactions such as redness, swelling, or itching.
• Weight gain due to increased caloric storage.
• Lipodystrophy at the injection site, including lipohypertrophy.
• Transient nausea or abdominal discomfort.
• Headache or dizziness.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or fluid retention, potentially leading to heart failure exacerbation.
• Hypersensitivity leading to serum sickness‑like manifestations.
• Insulin antibody formation causing unpredictable glycemic response.
• Severe local infection at injection site.

These events may vary in frequency and severity among individuals.

When prescribing Humulin I (Isofano), clinicians consider several safety precautions to minimize risk and ensure appropriate use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during initiation, dose adjustments, and periods of illness.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Avoid use in patients with known hypersensitivity to human insulin or formulation excipients.
• Consider reduced dosing in the elderly or those with reduced caloric intake.
• Pregnancy and lactation should be managed only under specialist supervision.
• Store the product according to label instructions, protecting it from extreme temperatures.

Humulin I (Isofano) may interact with other agents that affect glucose metabolism or insulin pharmacodynamics.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, requiring careful monitoring.
• High‑dose corticosteroids that increase insulin resistance, potentially necessitating dose changes.
• MAO inhibitors, which may interfere with glucose regulation.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemia.
• Thiazide diuretics, which can raise blood glucose levels.
• Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations.
• ACE inhibitors or ARBs, which may enhance insulin sensitivity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function and insulin clearance.